Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Market Cap	4.09B +50.4%
Revenue (ttm)	743.48M -2.7%
Net Income	140.44M +2.6%
EPS	2.75 +2.7%
Shares Out	51.15M
PE Ratio	29.13
Forward PE	26.06
Dividend	0.94 (1.17%)
Ex-Dividend Date	Jul 14, 2025

Volume	107,015
Average Volume	160,478
Open	80.60
Previous Close	80.00
Day's Range	80.05 - 81.80
52-Week Range	45.52 - 85.00
Beta	0.30
RSI	54.26
Earnings Date	Feb 25, 2026

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,045
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2025, BME:ROVI's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.